SPOTLIGHT: Amgen boosts buyback


With its shares trading at the low end of its 52-week range, Amgen has boosted its stock buyback plan by $5 billion. Release | Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.